TNGX (Tango Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by TNGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-08-05 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-07-02 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-06-23 | Robert Azelby | Director | A | — | — |
| 2026-06-08 | Lesley Ann Calhoun | Director | A | — | — |
| 2026-06-08 | Mace Rothenberg | Director | A | — | — |
| 2026-06-08 | John B Ketchum | Director | A | — | — |
| 2026-06-08 | Sung Lee | Director | A | — | — |
| 2026-06-03 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-05-05 | Matthew Gall | Chief Financial Officer | A | — | — |
| 2026-05-05 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-05-01 | Sung Lee | Director | A | — | — |
| 2026-04-16 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-04-02 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-03-27 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-03-09 | Adam Crystal | President, R&D | Sell | — | — |
| 2026-02-27 | Adam Crystal | President, R&D | Sell | — | — |
| 2026-02-04 | Barbara Weber | Director, Executive Chair | MIXED | — | — |
| 2026-02-04 | Adam Crystal | President, R&D | MIXED | — | — |
| 2026-02-04 | Daniella Beckman | Chief Financial Officer | MIXED | — | — |
| 2026-01-12 | Malte Peters | President & CEO | A | — | — |
| 2026-01-06 | Sung Lee | Director | A | — | — |
| 2025-11-04 | Malte Peters | Director | A | — | — |
| 2025-10-27 | TRV GP IV, LLC | 10%+ Owner | Sell | — | — |
| 2025-09-29 | TRV GP IV, LLC | 10%+ Owner | Sell | — | — |
| 2025-09-17 | Third Rock Ventures IV, L.P. | 10%+ Owner | Sell | — | — |
| 2025-09-09 | TRV GP IV, LLC | 10%+ Owner | Sell | — | — |
| 2025-08-26 | TRV GP IV, LLC | 10%+ Owner | Sell | — | — |
| 2025-08-21 | TRV GP IV, LLC | 10%+ Owner | Sell | — | — |
| 2025-06-09 | John B Ketchum | Director | A | — | — |
| 2025-06-09 | Lesley Ann Calhoun | Director | A | — | — |
| 2025-06-09 | Malte Peters | Director | A | — | — |
| 2025-06-09 | Alexis Borisy | Director | A | — | — |
| 2025-06-09 | Mace Rothenberg | Director | A | — | — |
| 2025-02-06 | Adam Crystal | See Remarks | Sell | — | — |
| 2025-02-06 | Barbara Weber | Chief Executive Officer | Sell | — | — |
| 2025-02-06 | Douglas Barry | General Counsel | Sell | — | — |
| 2025-02-06 | Daniella Beckman | Chief Financial Officer | Sell | — | — |
| 2025-02-05 | Daniella Beckman | Chief Financial Officer | A | — | — |
| 2025-02-05 | Douglas Barry | General Counsel | A | — | — |
| 2025-02-05 | Barbara Weber | Chief Executive Officer | A | — | — |
| 2025-02-05 | Adam Crystal | See Remarks | A | — | — |
| 2024-11-18 | Mace Rothenberg | Director | Buy | — | — |
| 2024-11-08 | EcoR1 Capital, LLC | 10%+ Owner | Sell | — | — |
| 2024-11-07 | Boxer Capital Management, LLC | — | Sell | — | — |
| 2024-10-28 | Aaron I. Davis | — | Sell | — | — |
| 2024-10-23 | Boxer Capital Management, LLC | — | Sell | — | — |
| 2024-09-17 | TRV GP IV, LLC | 10%+ Owner | Sell | — | — |
| 2024-09-09 | Third Rock Ventures GP IV, L.P. | 10%+ Owner | Sell | — | — |
| 2024-09-05 | Aaron I. Davis | — | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 16,926,475 | — |
| — | 10%+ Owner | 14,363,975 | — |
| — | — | 13,937,092 | — |
| — | 10%+ Owner | 13,386,574 | — |
| — | 10%+ Owner | 11,836,178 | — |
| — | 10%+ Owner | 8,203,642 | — |
| — | — | 7,432,435 | — |
| — | Director | 6,799,435 | — |
| — | Director, Executive Chair | 1,629,587 | — |
| — | President & CEO | 367,500 | — |
| — | — | 208,793 | — |
| — | Chief Financial Officer | 184,410 | — |
| — | Chief Scientific Officer | 167,584 | — |
| — | President, R&D | 142,743 | — |
| — | General Counsel | 66,014 | — |
| — | Director | 41,500 | — |
| — | Chief Financial Officer | 40,000 | — |
| — | Director | 24,937 | — |
| — | Director | 22,870 | — |
| — | Director | 17,500 | — |
| — | Director | 16,500 | — |
| — | Director | 5,740 | — |
| — | Director | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNGX quote page; the site-wide leaderboard is on the insider transactions hub.